Neogen Announces First-Quarter 2024 Results

Neogen Corporation (NASDAQ: NEOG) announced today the results of the first quarter ended August 31, 2023.

  • Revenue of $229.0 million, an increase of 73.0% over the prior-year quarter.
  • Net income of $1.5 million; $0.01 per diluted share.
  • Adjusted Net Income of $23.7 million; $0.11 per diluted share.
  • Adjusted EBITDA of $52.4 million, an increase of 93.8% over the prior-year quarter, at a margin of 22.9%.

LANSING, Mich., Oct. 10, 2023 /PRNewswire/ --Neogen Corporation (NASDAQ: NEOG) announced today the results of the first quarter ended August 31, 2023.

“Our performance in the quarter was generally in line with our expectations,” said John Adent, Neogen’s President and Chief Executive Officer. “Our legacy Food Safety business performed well, particularly in our core product lines of allergen, natural toxin and microbiological testing. The Animal Safety business experienced continued destocking, as anticipated, with channel inventory levels reaching multi-year lows. Pro forma growth in the former 3M Food Safety Division was low, impacted by the strong fourth quarter that saw us catch up on fulfillment and also by weakness in China, but the progress we made last quarter on Petrifilm supply at our transition manufacturing partner was sustained and initial demand in the second quarter has been encouraging. Our teams are leveraging this supply continuity, as well as the broader Neogen product portfolio, in targeted demand-generation initiatives.”

Adent continued, “We made significant progress in the quarter across a number of fronts related to the integration of the former 3M Food Safety division, moving closer to full autonomy of that business within the One Neogen we are building. We have additional key integration activities underway and remain on track for the third-quarter relocation of two product lines and exit of two transition agreements, and the construction of our new facility in Lansing is progressing well. With our combined commercial and technical teams approaching one year of working together on the product portfolio, we are excited about the momentum that’s building and remain as optimistic as ever regarding the future of the business.”

Financial and Business Highlights

Revenues for the first quarter were $229.0 million, an increase of 73.0% compared to $132.3 million in the prior year. Core revenue, which excludes the impacts of foreign currency translation, as well as acquisitions completed and product lines discontinued in the last 12 months, declined 1.3%. Acquisitions and discontinued product lines contributed 73.5% to revenue growth, while foreign currency added 0.8%.

Net income for the first quarter was $1.5 million, or $0.01 per diluted share, compared to $5.2 million, or $0.05 per diluted share, in the prior-year period. The decrease in net income was driven primarily by interest expense and the amortization of acquisition-related intangibles, all related to the merger with the former 3M Food Safety Division completed on September 1, 2022, partially offset by incremental revenues from the merger, which generated margins higher than the legacy company average margins. Adjusted Net Income was $23.7 million, or $0.11 per diluted share, compared to $17.6 million, or $0.16 per diluted share, in the prior-year period. Higher Adjusted EBITDA drove the increase in Adjusted Net Income, more than offsetting the increase in interest expense. On a per-share basis, Adjusted Net Income was lower by $0.05 in the first quarter compared to the prior-year period, a result of the increase in shares outstanding related to the 3M Food Safety transaction.

Gross margin was 51.0% in the first quarter of fiscal 2024. This compares to a gross margin of 47.0% in the same quarter a year ago, with the increase primarily due to higher gross margins generated by incremental revenues from the former 3M Food Safety Division.

First-quarter Adjusted EBITDA was $52.4 million, representing an Adjusted EBITDA Margin of 22.9%, compared to $27.0 million and a margin of 20.4% in the prior-year period. The margin expansion was primarily driven by the increase in gross profit, which more than offset a non-recurring billing adjustment from the Company’s transition manufacturing partner and operating expenses added during the quarter to accommodate the expanded scale of the business.

Food Safety Segment

Revenues for the Food Safety segment were $166.3 million in the first quarter, an increase of 157.2% compared to $64.6 million in the prior year, consisting of 4.5% core growth, 150.7% from acquisitions and discontinued product lines and a foreign currency benefit of 2.0%. Core revenue growth was led by the Bacterial & General Sanitation product category, which benefited from new microbiological testing business in the U.S. and the U.K., and by solid growth in the Natural Toxins & Allergens product category. The Indicator Testing, Culture Media & Other product category experienced a core revenue decline, driven primarily by international distributor ordering patterns for food quality and nutritional analysis products.

Animal Safety Segment

Revenues for the Animal Safety segment were $62.7 million in the first quarter, compared to $67.7 million in the prior year’s first quarter, consisting of a 6.7% core revenue decline, a 0.3% headwind from discontinued product lines and negative foreign currency impact of 0.4%. The core revenue decline was driven by the Veterinary Instruments & Disposables product category, which experienced continued destocking by large veterinary distributors, and the Animal Care & Other product category, which had lower sales of small-animal supplements and vitamin injectables, due in part to supply constraints. These decreases were partially offset by growth in the Rodent Control, Insect Control and Cleaners & Disinfectants product category.

The Company’s worldwide genomics business declined modestly in the quarter, with strength in sheep and beef testing in Australia and new business in beef markets in the U.K. and Brazil offset by decreases in porcine and poultry testing, due to the attrition of two large domestic customers.

Liquidity and Capital Resources

As of August 31, 2023, the Company had total cash and investments of $239.3 million and total outstanding debt of $900.0 million, as well as committed borrowing headroom of $150.0 million.

Fiscal Year 2024 Outlook

Taking into account first-quarter results, as well as typical seasonality of revenue and the expectation of an improved end-market environment in the second half of the year, the Company continues to anticipate fiscal year 2024 revenue between $955 million and $985 million, while Adjusted EBITDA continues to be expected in a range of $235 million to $255 million. The Company also continues to expect capital expenditures to be approximately $130 million, including approximately $100 million related specifically to the integration of the former 3M Food Safety Division.

Conference Call and Webcast

Neogen Corporation will host a conference call today at 8:00 a.m. Eastern Time to discuss the Company’s financial results. The live webcast of the conference call and accompanying presentation materials can be accessed through Neogen’s website at neogen.com/investor-relations. For those unable to access the webcast, the conference call can be accessed by dialing (844) 757-5681 (U.S.) or +1 (412) 317-5297 (International) and requesting the Neogen Corporation First Quarter FY24 Earnings Call (Conference ID: 10182677). A replay of the conference call and webcast will be available shortly following the conclusion of the call, and can be accessed domestically or internationally by dialing (877) 344-7529 or +1 (412) 317-0088, respectively, and providing the entry code 6567809, or through Neogen’s Investor Relations website at neogen.com/investor-relations.

About Neogen

Neogen is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen Corporation has developed comprehensive solutions spanning the Food Safety, Livestock and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the company’s most recently filed Form 10-K.

NEOGEN CORPORATION
UNAUDITED CONSOLIDATED STATEMENT OF INCOME
(In thousands, except for per share)

Three Months Ended August 31,

2023

2022

Revenue

Food Safety

$

166,278

$

64,643

Animal Safety

62,709

67,706

Total revenue

228,987

132,349

Cost of revenues

112,226

70,079

Gross profit

116,761

62,270

Operating expenses

Sales & marketing

45,783

23,383

Administrative

45,121

27,944

Research & development

6,722

4,881

Total operating expenses

97,626

56,208

Operating income

19,135

6,062

Other (expense) income

(17,472)

597

Income before tax

1,663

6,659

Income tax

160

1,450

Net income

$

1,503

$

5,209

Net income per diluted share

$

0.01

$

0.05

Shares to calculate per share amount

216,846,106

107,857,477

NEOGEN CORPORATION
UNAUDITED CONSOLIDATED BALANCE SHEET
(In thousands)

August 31, 2023

May 31, 2023

Assets

Current Assets

Cash and cash equivalents

$

178,832

$

163,240

Marketable securities

60,424

82,329

Accounts receivable, net of allowance of $3,205 and $2,827

137,669

153,253

Inventories, net

140,692

133,812

Prepaid expenses and other current assets

66,176

53,297

Total Current Assets

583,793

585,931

Net Property and Equipment

221,090

198,749

Other Assets

Right of use assets

14,505

11,933

Goodwill

2,137,602

2,137,496

Intangible assets, net

1,588,066

1,605,103

Other non-current assets

16,049

15,220

Total Assets

$

4,561,105

$

4,554,432

Liabilities and Stockholders’ Equity

Current Liabilities

Current portion of finance lease

$

2,642

$

-

Accounts payable

90,210

76,669

Accrued compensation

14,863

25,153

Income tax payable

5,399

6,951

Accrued interest

3,438

11,149

Deferred revenue

3,789

4,616

Other accruals

17,789

20,934

Total Current Liabilities

138,130

145,472

Deferred Income Tax Liability

354,792

353,427

Non-current debt

886,177

885,439

Other non-current liabilities

35,831

35,877

Total Liabilities

1,414,930

1,420,215

Commitments and Contingencies (note 12)

Equity

Preferred stock, $1.00 par value, 100,000 shares authorized, none issued
and outstanding

Common stock, $0.16 par value, 315,000,000 shares authorized,
216,310,582 and 216,245,501 shares issued and outstanding at August 31,
2023, and May 31, 2023, respectively

34,610

34,599

Additional paid-in capital

2,571,517

2,567,828

Accumulated other comprehensive loss

(26,496)

(33,251)

Retained earnings

566,544

565,041

Total Stockholders’ Equity

3,146,175

3,134,217

Total Liabilities and Stockholders’ Equity

$

4,561,105

$

4,554,432

NEOGEN CORPORATION
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

Three Months Ended August 31,

2023

2022

Cash Flows From (For) Operating Activities

Net income

$

1,503

$

5,209

Adjustments to reconcile net income to net cash from operating activities:

Depreciation and amortization

28,734

5,729

Deferred income taxes

998

(1,439)

Share-based compensation

2,638

1,867

Amortization of debt issuance costs

860

Change in operating assets and liabilities, net of business acquisitions:

Accounts receivable, net

16,242

4,819

Inventories

(6,304)

(8,330)

Prepaid expenses and other current assets

(12,925)

(14,682)

Accounts payable and accrued liabilities

4,980

(13,278)

Interest expense accrual

(7,711)

Change in other assets and liabilities

(6,006)

5,962

Net Cash From (For) Operating Activities

23,009

(14,143)

Cash Flows (For) From Investing Activities

Purchases of property, equipment and other non-current intangible assets

(30,630)

(12,996)

Proceeds from the maturities of marketable securities

21,905

108,488

Purchases of marketable securities

(12,523)

Proceeds from the sale of property and equipment and other

41

Business acquisitions, net of working capital adjustments and cash acquired

(1,331)

Net Cash (For) From Investing Activities

(8,684)

81,638

Cash Flows From Financing Activities

Exercise of stock options and issuance of employee stock purchase plan shares

1,062

905

Net Cash From Financing Activities

1,062

905

Effect of Foreign Exchange Rates on Cash

205

5,775

Net Increase In Cash and Cash Equivalents

15,592

62,625

Cash and Cash Equivalents, Beginning of Period

163,240

44,473

Cash and Cash Equivalents, End of Period

$

178,832

$

107,098

Non-GAAP Financial Measures

This press release includes certain non-GAAP financial measures, which management believes are useful to investors, securities analysts and other interested parties. Management uses Adjusted EBITDA as a key profitability measure. This is a non-GAAP measure that represents EBITDA before certain items that impact comparison of the performance of our business, either period-over-period or with other businesses. Adjusted EBITDA Margin is Adjusted EBITDA for a particular period expressed as a percentage of revenues for that period.

Management uses Adjusted Net Income as an additional measure of profitability. Adjusted Net Income is a non-GAAP measure that represents net income before certain items that impact comparison of the performance of our business, either period-over-period or with other businesses.

Core revenue growth is a non-GAAP measure that represents net sales for the period excluding the effects of foreign currency translation rates and the first-year impacts of acquisitions and discontinued product lines, where applicable. Core revenue growth is presented to allow for a meaningful comparison of year-over-year performance without the volatility caused by foreign currency translation rates, or the incomparability that would be caused by the impact of an acquisition, disposal or product line discontinuation.

These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP. Please see below for a reconciliation of historical non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with GAAP.

NEOGEN CORPORATION
RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA
(In thousands, except for percentages)

Three Months Ended August 31,

2023

2022

Net income

$

1,503

$

5,209

Provision for income taxes

160

1,450

Depreciation and amortization

28,734

5,729

Interest expense (income), net

16,666

(969)

EBITDA

$

47,063

$

11,419

Share-based compensation

2,638

1,867

FX transaction gain on loan revaluation (1)

(290)

Certain transaction fees and integration costs

1,951

13,732

Restructuring

559

Contingent consideration adjustments

300

ERP expense (2)

128

Discontinued product line expense

20

Adjusted EBITDA

$

52,369

$

27,018

Adjusted EBITDA margin (% of sales)

22.9

%

20.4

%

Adjusted EBITDA increase

93.8

%

(1)

Net foreign currency transaction gain associated with the revaluation of non-functional currency intercompany loans established in connection with 3M Food Safety transaction.

(2)

Non-capitalizable expenses related to ERP implementation.

NEOGEN CORPORATION
RECONCILIATION OF NET INCOME TO ADJUSTED NET INCOME
(In thousands, except for per share)

Three Months Ended August 31,

2023

2022

Net income

$

1,503

$

5,209

Amort of acquisition-related intangibles

23,325

1,841

Share-based compensation

2,638

1,867

FX transaction gain on loan revaluation (1)

(290)

Certain transaction fees and integration costs

1,951

13,732

Restructuring

559

Contingent consideration adjustments

300

ERP expense (2)

128

Discontinued product line expense

20

Estimated tax effect of above adjustments (3)

(6,447)

(5,093)

Adjusted Net Income

$

23,687

$

17,556

Adjusted Earnings per Share

$

0.11

$

0.16

(1)

Net foreign currency transaction gain associated with the revaluation of non-functional currency intercompany loans established in connection with 3M Food Safety transaction.

(2)

Non-capitalizable expenses related to ERP implementation.

(3)

Tax effect of adjustments is calculated using projected effective tax rates for each applicable item.

Contact
Bill Waelke
(517) 372-9200
ir@neogen.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neogen-announces-first-quarter-2024-results-301951692.html

SOURCE Neogen Corporation


Company Codes: NASDAQ-NMS:NEOG
MORE ON THIS TOPIC